Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
NCT06928272 · View on ClinicalTrials.gov ↗
Study Summary
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Pirfenidone
- DRUG Placebo for pirfenidone
- DRUG Placebo for upadacitinib
Study Locations (8)
Quebec
- Institut de Recherches Cliniques de Montréal (IRCM) — Montreal
- Centre de Recherche du CHUS (CRCHUS) — Sherbrooke
Roma
- INMI Lazzaro Spallanzani IRCCS — Roma
- Sapienza Università di Roma — Roma
California
- Laura Rodriguez Research Institute — San Diego
Rio de Janerio
- Ini-Fiocruz — Rio de Janeiro
Kampala
- Joint Clinical Research Centre (JCRC) — Kampala
Lusaka Province
- University Teaching Hospital — Lusaka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06928272
The ClinicalTrials.gov registry entry for NCT06928272 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Douglas D. Fraser, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 4 interventions — of which Upadacitinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06928272 reports 8 study locations spanning 6 distinct geographic areas — top geographies include Quebec, Roma, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06928272 about?
NCT06928272 is a clinical study titled "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study". The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three m...
What is the current status of trial NCT06928272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2025-09-10. Estimated completion is 2027-12.
What conditions does trial NCT06928272 study?
This clinical trial studies the following conditions: Long COVID. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06928272?
The interventions under investigation include: Upadacitinib (DRUG), Pirfenidone (DRUG), Placebo for pirfenidone (DRUG), Placebo for upadacitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06928272?
This trial is sponsored by Douglas D. Fraser, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06928272 being conducted?
This trial has 8 study locations across California, Rio de Janerio, Quebec, Roma, Kampala. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.